Predicting the 3-Dimensional Dose Distribution of Multilesion Lung Stereotactic Ablative Radiation Therapy With Generative Adversarial Networks.

Purpose: Because SABR therapy is being used to treat greater numbers of lung metastases, selecting the optimal dose and fractionation to balance local failure and treatment toxicity becomes increasingly challenging. Multilesion lung SABR therapy plans include spatially diverse lesions with heterogeneous prescriptions and interacting dose distributions. In this study, we developed and evaluated a generative adversarial network (GAN) to provide real-time dosimetry predictions for these complex cases.

Prospective evaluation of quantitative response parameter in patients with Gastrointestinal Stroma Tumor undergoing tyrosine kinase inhibitor therapy-Impact on clinical outcome.

The purpose of this study was to determine if dual-energy CT (DECT) vital iodine tumor burden (ViTB), a direct assessment of tumor vascularity, allows reliable response assessment in patients with GIST compared to established CT criteria such as RECIST1.1 and modified Choi (mChoi). From 03/2014 to 12/2019, 138 patients (64 years [32-94 years]) with biopsy proven GIST were entered in this prospective, multi-center trial.

Distinguishing recurrence from radiation-induced lung injury at the time of RECIST progressive disease on post-SABR CT scans using radiomics.

Stereotactic ablative radiotherapy (SABR) is a highly effective treatment for patients with early-stage lung cancer who are inoperable. However, SABR causes benign radiation-induced lung injury (RILI) which appears as lesion growth on follow-up CT scans. This triggers the standard definition of progressive disease, yet cancer recurrence is not usually present, and distinguishing RILI from recurrence when a lesion appears to grow in size is critical but challenging.

Predicting the need for a replan in oropharyngeal cancer: A radiomic, clinical, and dosimetric model.

Background: Patients with oropharyngeal cancer (OPC) treated with chemoradiation can experience weight loss and tumor shrinkage, altering the prescribed treatment. Treatment replanning ensures patients do not receive excessive doses to normal tissue. However, it is a time- and resource-intensive process, as it takes 1 to 2 weeks to acquire a new treatment plan, and during this time, overtreatment of normal tissues could lead to increased toxicities.

External validation of a CT-based radiomics signature in oropharyngeal cancer: Assessing sources of variation.

Background And Purpose: Radiomics is a high-throughput approach that allows for quantitative analysis of imaging data for prognostic applications. Medical images are used in oropharyngeal cancer (OPC) diagnosis and treatment planning and these images may contain prognostic information allowing for treatment personalization. However, the lack of validated models has been a barrier to the translation of radiomic research to the clinic.